Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 322

Flavin flaunts return to university venturing

Portal Innovations will target biomedical spinouts from across the Midwest under the direction of ex-UChicago innovation veteran John Flavin.

Mar 9, 2020

Woodford sounds out appetite for $655m fund

Neil Woodford could return to the stage with a bid for some of his old assets should ongoing talks with unnamed UK-based institutional investors and wealth managers succeed.

Mar 9, 2020

Corporate venturing deal net: 2-6 March 2020

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Mar 6, 2020

Culture Biosciences gets $15m funding reaction

MIT Media Lab-affiliated E14 Fund has invested in the biomanufacturing software provider as part of a series A round led by Cultivian Sandbox Ventures.

Mar 6, 2020

Recipharm returns for latest Cinclus round

Cinclus Pharma has lured back corporate venturing unit Recipharm Venture Fund for a $26.4m round that will fund a phase 2 study for its GERD therapy candidate.

Mar 6, 2020

GV helps pump series C funding into Element

The wearable defibrillator developer, founded by Stanford adjunct professor Uday Kumar, has raised more than $145m that will support the launch of its lead product.

Mar 6, 2020

Oric originates IPO filing

The Taiho Ventures, Memorial Sloan and Hartford HealthCare Endowment-backed cancer drug developer has filed to raise up to $86.3m.

Mar 5, 2020

Novartis helps plant $100m in Pliant

Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.

Mar 4, 2020

GV helps pump series C funding into Element

The wearable defibrillator developer revealed GV is an existing investor as it raised more than $145m that will support the launch of its lead product.

Mar 4, 2020

Novartis helps plant $100m in Pliant

Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.

Mar 4, 2020
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here